A UK company is about to start a Phase 1 trial with the drug involving 18 healthy human volunteers and the results are expected to be announced later this year.
In an earlier Phase 1 study in nine healthy human volunteers, the treatment was seen to reduce the excretion of sebum by the skin, which is associated with acne development, by up to 70 pct.
?The Phase I results are startlingly good,? said Nigel Blackburn, director of clinical development at the company, Summit, which is organising the trial.
?Reducing sebum production has been the ?holy grail? of acne treatment for 30 years, and there has been little success aside from Roaccutane which has significant side effects,? he added.
The current ?gold standard? for acne treatment, Roaccutane can cause a wide range of side effects, including teratogenicity ? which leads to abnormalities in the unborn foetus of pregnant women, and has also recently been linked to depression and (inconclusively) to teenage suicides. The market for acne treatments is worth several billion dollars, and any new treatment developed without side effects could potentially reap blockbuster sales.
Although Summit has not disclosed the name of the drug now under evaluation, the company says it represents an entirely new class of compounds for treating acne.
No comments:
Post a Comment